Clinical outcomes in statin treatment trials: A meta-analysis

Archives of Internal Medicine

Volumn 159, Issue 15, 1999, Pages 1793-1802

  Ross, Susan D ^a   Allen, I Elaine ^a   Connelly, Janet E ^a   Korenblat, Bonnie M ^b   Smith, M Eugene ^b   Bishop, Daren ^a   Luo, Don ^a  

^a MetaWorks Inc   (United States)

^b BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE;

ANTICHOLESTEREMIC AGENTS; CAUSE OF DEATH; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LOVASTATIN; ODDS RATIO; PRAVASTATIN; RANDOMIZED CONTROLLED TRIALS; SIMVASTATIN; TREATMENT OUTCOME;

EID: 0033598084     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.15.1793     Document Type: Article

References (74)

1. Pfeffer MA, Sacks FM, Moye LA, et al, for the CARE Investigators. Cholesterol and Recurrent Events: a secondary prevention trial far normolipidemic patients. Am J Cardiol. 1995;76:98C-106C.
2. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335: 1001-1009.
3. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial (CARE) investigators. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels alter acute myocardial infarction [published erratum appears in AmJCardiol. 1992;69:574]. Am J Cardiol. 1991; 68:1436-1446.
4. The West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. Am J Cardiol. 1997;79:756-762.
5. The West of Scotland Coronary Prevention Study Group. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. Am J Cardiol. 1995;76:485-491.
6. Ford I. Computerised record linkage compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. J Clin Epidemiol. 1995;48:1441-1452.
7. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
8. Shepherd J, Cobbe SM, Lorimer AR, et al, for the West of Scotland Coronary Prevention Study Group. Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet. 1996;348:1339-1342.
9. Shepherd J, for the West of Scotland Coronary Prevention Study Group. A trial of cholesterol reduction in Scottish men. Am J Cardiol. 1995;76:113C-117C.
10. Chalmers TC, Lau J. Meta-analytic stimulus for changes in clinical trials. Stat Methods Med Res. 1993;2:161-172.
11. Sacks MS, Berrier J, Reitman D, Ancona-Berk V, Chalmers T. Meta-analyses of randomized controlled trials. N Engl J Med. 1987;316:450-455.
12. Sacks HS, Berrier J, Reitman D, Pagano D, Chalmers T. Meta-analyses of randomized control trials: an update of the quality and methodology. In: Bailar JC III, Mosteller F, eds. Medical Uses of Statistics. 2nd ed. Boston, Mass: NEJM Books; 1992:427-442.
13. Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
14. The Scandinavian Simvastatin Survival Study (4S) Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet. 1994; 344:1383-1389.
15. Hippisley-Cox J. Lowering patients' cholesterol, extrapolating results of trial of simvastatin gives room for doubt. BMJ. 1995;311:690-691.
16. Kjekshus J, Pedersen TR. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1995;76:64C-68C
17. Leino M, Pyorala K, Lehto S, Rantala A. Lens opacity in patients with hypercholesterolemia and ischaemic heart disease, electronic lens opacity measurements. Doc Ophthalmol. 1992;80:309-315.
18. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1996;156:2085-2092.
19. Gotto GM. Lipid-lowering trials: what have they taught us about morbidity and mortality? Cardiology. 1996;87:453-457.
20. The Prospective Pravastatin Pooling Project Investigators. Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project: a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol. 1995;76:899-905.
21. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:19-48.
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177-188.
23. Fleiss J. Statistical Methods for Rates and Proportions. New York, NY: John Wiley & Sons; 1973.
24. Yates F. Contingency tables involving small numbers and the chi-squared test. J R Stat Soc. 1934;1:217-235.
25. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728-1733.
26. Holme I. Relationship between total mortality and cholesterol reduction as found by meta-regression analysis of randomized cholesterol-lowering trials. Control Clin Trials. 1996;17:13-22.
27. Smith GD, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ. 1993;306:1367-1373.
28. LaRosa JC, Applegate W, Grouse JR III, et al. Cholesterol lowering in trie elderly: results of the Cholesterol Reduction ir Seniors Program (CRISP) pilot study. Arch Intern Med. 1994;154:529-539.
29. Stoy DB, Curtis RC, Dameworth KS, et al. The successful recruitment of elderly black subjects in a clinical trial: the Cholesterol Reduction in Seniors Program (CRISP) experience. J Natl Med Assoc. 1995;87:280-287.
30. Chan P, Tomlinson B, Lee CB, Pan WH, Lee YS. Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects. Hypertension. 1996;28:647-651.
31. Santinga JT, Rosman HS, Rubenfire M, et al. Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia. AmJ Med. 1994;96:509-515.
32. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/L (200 to 300 mg/dL) plus two additional atherosclerotic risk factors. Am J Cardiol. 1993;72:1031-1037.
33. Adams HP, Byington RP, Hoen H, Dempsey R, Furberg CD. Effect of cholesterollowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. Cerebrovasc Dis. 1995;5:171-177.
34. The ACAPS Group. Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). Control Clin Trials. 1992;13:293-314.
35. Espeland MA, Applegate W, Furberg CD, Lefkowitz D, Rice L, Hunninghake D, for the ACAPS investigators. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. Am J Epidemiol. 1995;142:1011-1019.
36. Furberg CD, Adams HP Jr, Applegate WB, for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90:1679-1687.
37. Probstfield JL, Margitic SE, Byington RP, Espeland MA, Furberg CD. Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study. Am J Cardiol. 1995;76:47C-53C.
38. Mercuri M, Bond MG, Sirtori CR, et al, for the Carotid Atherosclerosis Italian Ultrasound Study. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population. Am J Med. 1996;101:627-634.
39. Waters D, Higginson L, Gladstone P, et al, for the Canadian Coronary Athero sclerosis Intervention Trial. Effects of monotherapy with an HMG CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. Circulation. 1994;9:959-968.
40. Waters D, Higginson L, Gladstone P, Boccuzzi SJ, Cook T, Lesperance J. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women: a Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) subsludy. Circulation. 1995;92:2404-2410.
41. Waters D, Higginson L, Gladstone P, Kimball B, LeMay M, Lesperance J, for the Canadian Coronary Atherosclerosis Intervention Trial Investigators. Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease. Control Clin Trials. 1993; 14:45-74.
42. Waters D, Lesperance J, Gladstone P, et al, for the Canadian Coronary Atherosclerosis Intervention Trial Study Group. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis: a Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. Circulation. 1996;94:614-621.
43. Bestehorn HP, Rensing UFE, Roskamm H, et al. The effect of simvastatin on progression of coronary artery disease: the multi-center Coronary Intervention Study (CIS). Eur Heart J. 1997;18:226-234.
44. Salonen R, Nyssonen K, Porkkala-Sarataho E, Salonen JT. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol. 1995;76:34C-39C.
45. Salonen R, Nyyssonen K, Porkkala E, et al. The Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 1995;92:1758-1764.
46. Oliver MF, Defeyter PJ, Lubsen J, et al, for the MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) [published erratum appears in Lancet. 1994;344:762]. Lancet, 1994;344:633-638.
47. Alaupovic P, Hodis HN, Knight-Gibson C, et al. Effects of lovastatin on ApoA-and ApoB-containing lipoproteins: families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS). Arterioscler Thromb. 1994;14:1906-1913.
48. Blankenhorn DH, Azen SP, Kramsch DM, et al, for the MARS Research Group. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:969-976.
49. Hodis HN, Mack WJ, Azen SP, et al. Triglyceride-and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994;90:42-49.
50. Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Ann Intern Med. 1996;124:548-556.
51. Furberg CD, Pitt B, Byington RP, Park JS, McGovern ME, for the PLAC I and PLAC II Investigators. Reduction in coronary events during treatment with pravastatin. Am J Cardiol. 1995;76:60C-63C.
52. Pitt B, Ellis SG, Mancini GB, Rosman HS, McGovern ME. Design and recruitment in the United States of a multicenter quantitative angiographic trial of Pravastatin to Limit Atherosclerosis in the Coronary Arteries (PLAC I). Am J Cardiol. 1993;72:31-35.
53. Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): reduction in atherosclerosis progression and clinical events. JAm Coll Cardiol. 1995;26:1133-1139.
54. Crouse JR III, Byington RP, Bond MG, Espeland MA, Bond MG. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol. 1995; 76:54C-59C.
55. Crouse JR, Byington RP, Bond MG, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries: design features of a clinical trial with carotid atherosclerosis outcome. Control Clin Trials. 1992;13:495-506.
56. Furberg CD, Byington RP, Crouse JR, Espeland MA. Pravastatin, lipids, and major coronary events. Am J Cardiol. 1994;73:1133-1134.
57. Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
58. van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJ, Lie KI, Bruschke AV, for the REGRESS Study Group. Reduction of transient myocardial ischemia with Pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation. 1996;94:1503-1505.
59. Hebert PR, Gaziano JM, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med. 1995;155:50-55.
60. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA. 1997;278:313-321.
61. Downs JR, Clearafield M, Weis S, et al, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279: 1615-1622.
62. Simes RJ, Baker J, MacMahon S. Pravastatin reduces total mortality in patients with coronary heart disease and average cholesterol levels: relationship of baseline cholesterol and treatment effects in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) trial. J Am Coll Cardiol. 1998;31 (suppl 2A): 281A.
63. Tonkin AM. Management of the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1995;76:107C-112C.
64. Goldstein MR. Effects of lovastatin and pravastatin on coronary artery disease. Ann Intern Med. 1994;120:811-812.
65. Atkins D, Psaty BM, Koepsell TD, Longstreth WT, Larson EB. Cholesterol reduction and the risk for stroke in men: a meta-analysis of randomized controlled trials. Ann Intern Med. 1993;119:136-145.
66. Davies MJ. The composition of coronary artery plaques. N Engl J Med. 1997; 336:1312-1314.
67. Sackett DL, Richardson WS, Rosenberg W, Haynes RB. Evidence-Based Medicine. New York, NY: Churchill Livingstone; 1997.
68. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993; 153:154-183.
69. Ul Haq I, Ramsey LE, Pickin DM, et al. Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sci (Colch). 1996;91:399-413.
70. Marchioli R, Marfisi RM, Carinci F, Tognoni G. Meta-analysis, clinical trials, and transferability of research results into practice: the case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease. Arch Intern Med. 1996;156:1158-1172.
71. Buchwald H, Campos CT, Boen CT, et al. Gender-based mortality follow-up from the Program on the Surgical Control of the Hyperlipidemias (POSCH) and metaanalysis of lipid intervention trials: women in POSCH and other lipid trials. Ann Surg. 1996;224:486-498.
72. The Plaque Hypertension Lipid-Lowering Italian Study (PHYLLIS) Group. A protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolemic hypertensive subjects. J Hypertens. 1993;11(suppl 5):S314-S315.
73. West MS, Herd JA, Ballantyne CM, et al. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. Control Clin Trials. 1996; 17:550-583.
74. Keech A, Collins R, MacMahon S, et al. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J. 1994;15:255-269.